KIRKLAND, Wash., Sept. 19 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) has formed a new Device Division in order to develop, manufacture and market its patented line of stem cell cultivation and replication devices.
CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart.
Along with its planned human trials for its therapeutics, CellCyte Genetics intends to develop a new stem cell cultivation device or "bioreactor" unit for which CellCyte Genetics owns the worldwide patent and rights. The Company plans to market the device for applications that will require cells to be grown under regulated oxygen concentrations, e.g. the replication of stem cells and the culture of pancreatic islet cells prior to transplantation into diabetic patients.
Dr. Ron Berninger, Chief Scientific Officer of CellCyte Genetics explains, "CellCyte's patented biological cell maintenance system has the unique ability to incubate cultured cells with a very efficient and regulatable oxygen supply, making it an ideal choice for culturing cells that are otherwise difficult to keep alive or to expand. Inside the bioreactor, the cells can also form a 3-dimensional network, which is what most cell types do in major organs of the body."
A key element of this bioreactor is the capability to supply oxygen (by bundles of oxygen fibers) to the cells throughout the entire space in which cells are growing. Stem cells appear to be sensitive to oxygen levels and can be induced to replicate or differentiate in part by controlling the oxygen level.
Using CellCyte's product, scientists, researchers and clinicians should
be able to dramatically increase the number of stem cells available for
research and potentially for use in stem cell therapies. Management
believes that th
|SOURCE CellCyte Genetics Corporation|
Copyright©2007 PR Newswire.
All rights reserved